Search
Showing results for "1"
The deadline for ATAR exam special provisions is still open for newly diagnosed Type 1 Diabetes patients.
It may surprise you to know that the Australian government has invested almost $300 million dollars since 2000 towards research and clinical trials for diabetes
Honours/Masters scholarship - now open Applications are open for our Honours / Masters Scholarships with the purpose of providing funding for
To assess the real-world performance of MiniMed™ 780G for Australians with type 1 diabetes (T1D) following advanced hybrid closed loop (AHCL) activation and to evaluate the effect of changing from MiniMed 670/770G to 780G.
This analysis aimed to investigate diabetes-specific psychological outcomes among adults with type 1 diabetes (T1D) using hybrid closed-loop (HCL) versus standard therapy.
Copeptin is a surrogate marker for arginine vasopressin (AVP) release in response to hyperosmolal stimuli such as diabetic ketoacidosis (DKA). The objective of this work is to characterize kinetics of copeptin and osmolality, and their dynamic relationship during rehydration and insulin therapy in children with type 1 diabetes (T1D) and DKA.
Currently, DNA methylation is the most studied epigenetic phenomenon in large populations
The aim of this study is to investigate the antidepressant effects of N2O and N2O and SSRI combined.
A clinical trial-based economic evaluation was performed in which the net costs and effectiveness of the two treatment modalities were calculated and...
Without a booster dose, the effectiveness of 3 doses waned more rapidly from 2 to 4 years of age than previously documented for children >6 years of age who...